Tag: Polivy
After CAR T-Cell Relapse in Mantle Cell Lymphoma, a CD79b-Targeted ADC...
A single-patient case report describes a prolonged remission with polatuzumab vedotin (Polivy®; Genentech/Roche) plus bendamustine (Treanda®; Teva/Cephalon) and rituximab (Rituxan®; Genentech/Biogen) in mantle cell lymphoma (MCL) after CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The regimen is approved for diffuse large B-cell lymphoma, not mantle cell lymphoma, and its use in this setting remains investigational.
Polatuzumab Vedotin in the Treatment of Patients with Previously Untreated Diffuse...
Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...
European Regulators Approve Polatuzumab Vedotin, Triggering Milestone Payment for Seattle Genetics
The European Commission's conditional marketing authorization of polatuzumab vedotin (Polivy®; Genentech/Roche) earlier this week triggered a milestone payment which Seattle Genetics will receive from...
Polatuzumab Vedotin Shows Complete Response in R/R Diffuse Large B-cell Lymphoma
Polatuzumab vedotin (Polivy™; Genentech/Roche) in combination with bendamustine (Treanda®; Cephalon/Teva Pharmaceutical) and rituximab (Rituxan®; Genentech/Roche) shows encouraging rates of complete response (CR) among patients...
FDA Grants Accelerated Approval of Polatuzumab Vedotin in Select Patients
The U.S. Food and Drug Administration (FDA) today confirmed that it has granted accelerated approval of polatuzumab vedotin-piiq (Polivy™; Genentech; previously known as DCDS4501A...
